Market News / Story
Regeneron Expands Sanofi Antibody Pact; $1 Billion Upfront, Up to $7 Billion in Milestones
·
Regeneron entered into the Sixth Amendment to its Antibody License and Collaboration Agreement with Sanofi to co-develop and co-commercialize four new long-acting antibodies targeting IL-4, IL-13, IL-4Rα, and a bispecific IL-4xIL-13. Sanofi will pay $1.0 billion upfront, with up to $7.0 billion in potential development, regulatory, and commercial milestones. The parties will share global profits 50/50 and split development costs equally, with Regeneron covering costs…